Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anal Cancer
- Cervix Cancer
- Head and Neck Squamous Cell Carcinoma
- Penile Cancer
- Squamous Cell Lung Cancer
- Vulvar Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: 6 independent cohorts (head and neck, cervix, lung, anus, vulva, and penis) evaluating the association of pembrolizumab and vorinostatMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of pembrolizumab in combination with vorinostat in adult patients with recurrent and/or metastatic squamous cell carcinoma of different locations. Antitumor activity of the combination will be evaluated using th...
Open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of pembrolizumab in combination with vorinostat in adult patients with recurrent and/or metastatic squamous cell carcinoma of different locations. Antitumor activity of the combination will be evaluated using the objective response rate (ORR) during treatment (investigator assessment).
Tracking Information
- NCT #
- NCT04357873
- Collaborators
- Merck Sharp & Dohme Corp.
- Fondation ARC
- ERA-NET
- Investigators
- Principal Investigator: Christophe Le Tourneau, MD Institut Curie